Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study

Yi Liu, Zelin Ma, Shuxiao Ma, Abuduwaili Yasheng, Zelin Deng, Chenglin Guo, Lunxu Liu · 2026

Read Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study by Yi Liu, Zelin Ma, Shuxiao Ma, Abuduwaili Yasheng, Zelin Deng, Chenglin Guo, Lunxu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263860.txt.

Description

Yi Liu and colleagues asked in 2026 whether a gene rearrangement called ROS1 marks lung adenocarcinoma patients for earlier relapse, and found the answer depends on the tumor around it. Their records covered 3,162 patients with resected invasive tumors tested between 2018 and 2020. About four and a half percent carried the rearrangement.

In stage II to III disease, and in tumors that were solid, poorly differentiated, or pathologically aggressive, carriers relapsed sooner and died earlier. In stage I disease and in gentler-looking tumors, carriers fared the same as everyone else. The rearrangement clustered with non-smoking status and with invasion into lymph vessels. Carriers also spread to bone significantly more often. The authors advise folding ROS1 status into risk estimates only alongside stage and pathology. High-risk carriers may warrant closer bone surveillance.

Catalog record

CREATORYi Liu, Zelin Ma, Shuxiao Ma, Abuduwaili Yasheng, Zelin Deng, Chenglin Guo, Lunxu Liu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13263860

Browse the full library · About the Tower of Babel